LONDON - Oxford BioMedica plc made significant progress with its gene therapy portfolio, agreeing to a comprehensive deal for the commercialization of its LentiVector technology for use in research, and announcing it has achieved the industry's Holy Grail of generating cytotoxic T-cell responses with the cancer immunotherapeutic TroVax. (BioWorld International)